Vivimed Labs Limited · NSE:VIVIMEDLAB
Vivimed Labs — Q1 FY2013 Earnings Presentation
11 slides from Vivimed Labs's earnings presentation, 2012
Slide 1: Vivimed Labs Limited Earnings Presentation Q1 FY13
VIVIMED LABS LIMITED Earnings Presentation –Q1 - FY13
Slide 2: Disclaimer
DISCLAIMER No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all events not current after the d
Slide 3: Key Highlights
Key Highlights Q1-FY13 Consolidated Results: • Total Income reported at INR 2,743 mn, an increase of 127% YoY • EBITDA reported at INR 619 mn, an increase of 151% YoY o EBITDA Margin at 22.6% • Profit After Tax (PAT) reported at INR 261 mn, an increase of 110% YoY o PAT Margin at 9.5% • Diluted EPS
Slide 4: Quarterly Financial Performance - Consolidated
Quarterly Financial Performance - Consolidated Income Statement (INR Mn) Q1-FY13 Q1-FY12 YoY Change Q4-FY12 QoQ Change Total Income * 2,743 1,206 127% 2,520 9% Total Expenses 2,124 959 121% 2,048 4% EBITDA 619 247 151% 472 31% EBITDA Margin 22.6% 20.5% 210bps 18.7% 390bps Depreciation 141 26 442% 13
Slide 5: Quarterly Financial Performance - Standalone
Quarterly Financial Performance - Standalone Income Statement (INR Mn) Q1-FY13 Q1-FY12 YoY Change Q4-FY12 QoQ Change Total Income * 915 1,040 (12)% 913 0% Total Expenses 683 832 (18)% 679 1% EBITDA 232 208 12% 234 (1)% EBITDA Margin 25.4% 19.9% 550bps 25.6% (20)bps Depreciation 37 14 164% 46 (20)% I
Slide 6: Segmental Financial Performance
Segmental Financial Performance Consolidated Segmental Revenue* (INR Mn) Consolidated Segmental PBIT (INR Mn) * Consolidated Segmental Revenue excludes Inter Company Sales Standalone Segmental Revenue (INR Mn) Standalone Segmental PBIT (INR Mn) 6
Slide 7: Historical Consolidated Income Statement
Historical Consolidated Income Statement Income Statement (INR Mn) FY 09 FY 10 FY 11 FY12 Income 2,786 3,500 4,169 6,710 Total Expenses 2,305 2,795 3,319 5,380 EBITDA 481 705 850 1,330 EBITDA Margin 16.7% 20.2% 20.4% 19.7% Depreciation & Amortization 77 96 91 268 Interest 173 212 206 284 PBT 231 396
Slide 8: FY12 Consolidated Balance Sheet
FY12 Consolidated Balance Sheet Particulars FY 12 FY11 Particulars FY 12 FY11 A EQUITIES & LIABILITIES B ASSETS Part -1 Shareholder Funds Part -1 Non Current Assets (a) Share Capital – Equity 139 102 Share Capital – Preference 1,310 - (a) Fixed Assets 5,412 1,797 (b) Reserves & Surplus 3,275 1,777 (
Slide 9: Historical Consolidated Balance Sheet
Historical Consolidated Balance Sheet Figures in INR Mn Balance Sheet - Consolidated (INR Mn) FY 09 FY 10 FY 11 Share Capital 94 100 102 Equity Share Warrants 23 50 89 Reserves 908 1,299 1,777 Net worth 1,025 1,449 1,967 Loan Funds 3,005 2,353 3,077 Deferred Tax Liability 130 162 147 TOTAL LIABILITI
Slide 10: Capital Market Data
Capital Market Data Share Price Movement for Quarter ended Jun 29, 2012 Shareholding Pattern (As on Jun 30, 2012) 18000 450 Top 440 % 17500 Institutional 430 Holding Shareholders 420 17000 410 Kitara Piin 13.1% 16500 400 390 Emerging India 2.0% 16000 Focus Fund 380 370 15500 DSP Blackrock 1.5 % 360
Slide 11: Thank you
Thank you For further details please feel free to contact our Investor Relations Representatives: Anuj Sonpal AARNINE Financial Markets Advisory LLP Tel: +91-22-2204-0763/64/65 Email: asonpal@aarnine.com 11